Bard Announces First Quarter Results

Diluted EPS of $1.08, $1.44 on Adjusted Basis

MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today reported 2013 first quarter financial results. First quarter 2013 net sales were $740.3 million, an increase of 1 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2013 net sales also increased 1 percent over the prior-year period.

For the first quarter 2013, net sales in the U.S. were $498.5 million, essentially flat to net sales of $496.2 million in the prior-year period. Net sales outside the U.S. were $241.8 million, an increase of 3 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2013 net sales outside the U.S. also increased 3 percent over the prior-year period.

For the first quarter 2013, net income was $90.7 million and diluted earnings per share were $1.08, a decrease of 35 percent and 33 percent, respectively, as compared to first quarter 2012 results. Adjusting for items that affect comparability between periods as detailed in the tables below, first quarter 2013 net income was $120.7 million and diluted earnings per share were $1.44, a decrease of 13 percent and 11 percent, respectively, as compared to first quarter 2012 results.

Timothy M. Ring, chairman and chief executive officer, commented, “We are off to a strong start executing on our strategic investment plan that we announced last quarter. It’s a credit to our teams around the world that we have been able to hit our initial targets on such a broad and ambitious endeavor. The organization is energized and committed to improve the long-term growth trajectory of the business.”

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “forecast”, “plan”, “believe”, and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our December 31, 2012 Form 10-K for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.
Consolidated Statements of Income
(dollars and shares in thousands except per share amounts, unaudited)
							Quarter Ended
							March 31,
							2013			2012
Net sales							$	740,300		$	730,000
Costs and expenses
Cost of goods sold								295,300			279,400
Marketing, selling and administrative expense								216,400			202,300
Research and development expense								59,300			48,200
Interest expense								11,400			9,500
Other (income) expense, net								30,300			(800	)
Total costs and expenses								612,700			538,600
Income from operations before income taxes								127,600			191,400
Income tax provision								36,900			52,700
Net income							$	90,700		$	138,700
Basic earnings per share available to common shareholders							$	1.09		$	1.62
Diluted earnings per share available to common shareholders							$	1.08		$	1.60
Wt. avg. common shares outstanding - basic								81,300			84,100
Wt. avg. common and common equivalent shares outstanding - diluted								82,500			85,100
Product Group Summary of Net Sales
(dollars in thousands, unaudited)
	Quarter Ended March 31,
							Constant
	2013		2012		Change		Currency
Vascular	$	203,200	$	209,200	-3	%		-3	%
Urology		188,800		185,100	2	%		2	%
Oncology		207,100		198,900	4	%		4	%
Surgical Specialties		120,300		114,700	5	%		5	%
Other		20,900		22,100	-5	%		-6	%
Net sales	$	740,300	$	730,000	1	%
Foreign exchange impact				1,700
Constant Currency	$	740,300	$	731,700				1	%

Reconciliation of Earnings
(dollars in millions except per share amounts, unaudited)
	Quarter Ended March 31, 2013
																	Diluted
																	Earnings
				Marketing,													per Share
	Cost of			Selling and			Research &			Other							Available
	Goods			Administrative			Development			(Income)			Income		Net		to Common
	Sold			Expense			Expense			Expense, Net			Taxes		Income		Shareholders
GAAP Basis	$	295.3		$	216.4		$	59.3		$	30.3		$	36.9	$	90.7	$	1.08
Items that affect comparability of
results between periods:
Acquisition-related items		(0.2	)		(0.2	)		(0.4	)		0.1			-		0.7
Asset impairments		(1.9	)		-			-			(3.8	)		1.4		4.3
Litigation charges		-			-			-			(25.8	)		0.8		25.0
Total		(2.1	)		(0.2	)		(0.4	)		(29.5	)		2.2		30.0		0.36
Adjusted Basis	$	293.2		$	216.2		$	58.9		$	0.8		$	39.1	$	120.7	$	1.44
	Quarter Ended March 31, 2012
																	Diluted
																	Earnings
				Marketing,													per Share
	Cost of			Selling and			Research &			Other							Available
	Goods			Administrative			Development			(Income)			Income		Net		to Common
	Sold			Expense			Expense			Expense, Net			Taxes		Income		Shareholders
GAAP Basis	$	279.4		$	202.3		$	48.2		$	(0.8	)	$	52.7	$	138.7	$	1.60
Items that affect comparability of
results between periods:
Acquisition-related items		-			-			(0.4	)		(0.6	)		0.2		0.8		0.01
Adjusted Basis	$	279.4		$	202.3		$	47.8		$	(1.4	)	$	52.9	$	139.5	$	1.61

Notes to Reconciliation of Earnings

• For the three months ended March 31, 2013, the following items affected the comparability of results between periods: (i) charges of $0.7 million pre-tax for acquisition-related items including transaction costs, purchase accounting adjustments and integration costs; (ii) charges of $5.7 million pre-tax related to asset impairments; and (iii) charges of $25.8 million pre-tax related to litigation matters. The net effect of these items decreased net income by $30.0 million, or $0.36 diluted earnings per share available to common shareholders.
• For the three months ended March 31, 2012, a charge of $1.0 million pre-tax for acquisition-related items including transaction costs, purchase accounting adjustments and integration costs, affected the comparability of results between periods. The effect of this charge decreased net income by $0.8 million, or $0.01 diluted earnings per share available to common shareholders.

This press release contains financial measures that are not calculated in accordance with United States generally accepted accounting principles (GAAP). These non-GAAP measures are reconciled to their most directly comparable GAAP measures in the above tables.

This press release includes net sales excluding the impact of foreign exchange. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors.

In addition, this press release includes the following non-GAAP measures: (1) cost of goods sold excluding charges for acquisition-related items and an asset impairment; (2) marketing, selling and administrative expense excluding charges for acquisition-related items; (3) research and development expense excluding charges for acquisition-related items; (4) other (income) expense, net, excluding acquisition-related items, asset impairments and litigation charges; (5) income tax provision excluding the tax effect of the items set forth in (1) through (4) above; (6) net income excluding the items set forth in (1) through (5) above; and (7) diluted earnings per share available to common shareholders excluding the items set forth in (1) through (5) above.

The company excluded the items described above because they may cause certain statements of operations categories not to be indicative of ongoing operating results, and therefore affect the comparability of results between periods. The company therefore believes that these non-GAAP measures provide an additional and meaningful assessment of the company’s ongoing operating performance. Because the company has historically reported these non-GAAP results to the investment community, management also believes that the inclusion of these non-GAAP measures provides consistency in its financial reporting and facilitates investors’ understanding of the company’s historic operating trends by providing an additional basis for comparisons to prior periods. Management uses these non-GAAP measures: (1) to establish financial and operational goals; (2) to monitor the company’s actual performance in relation to its business plan and operating budgets; (3) to evaluate the company’s core operating performance and understand key trends within the business; and (4) as part of several components it considers in determining incentive compensation.

Management recognizes that the use of these non-GAAP measures has limitations, including the fact that they may not be comparable with similar non-GAAP measures used by other companies and that management must exercise judgment in determining which types of charges or other items should be excluded from the non-GAAP information. Management compensates for these limitations by providing full disclosure of each non-GAAP measure and a reconciliation to the most directly comparable GAAP measure. All non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be considered in isolation from, or as a replacement for, financial information prepared in accordance with GAAP. For a reconciliation of these non-GAAP measures to the most comparable GAAP measures, please see the above tables.

Notes to Earnings per Share (dollars and shares in thousands, except per share amounts, unaudited)
	Quarter Ended
	March 31,
	2013		2012
Earnings per Share Numerator: GAAP Basis - basic and diluted
Net income	$	90,700	$	138,700
Less: Income allocated to participating securities (1)		1,700		2,700
Net income available to common shareholders	$	89,000	$	136,000
Earnings per Share Numerator: Adjusted Basis - diluted
Net income	$	120,700	$	139,500
Less: Income allocated to participating securities (1)		2,200		2,700
Net income available to common shareholders	$	118,500	$	136,800
Earnings per Share Denominator:
Wt. avg. common shares outstanding - basic		81,300		84,100
Wt. avg. common and common equivalent shares outstanding - diluted		82,500		85,100
Earnings per Share: GAAP Basis
Basic earnings per share available to common shareholders	$	1.09	$	1.62
Diluted earnings per share available to common shareholders	$	1.08	$	1.60
Earnings per Share: Adjusted Basis
Diluted earnings per share available to common shareholders	$	1.44	$	1.61

(1) Basic and diluted earnings per share available to common shareholders is calculated using a numerator, which represents the total of net income attributable to common shareholders less income allocated to participating securities.